HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Anti-CD30 antibody conjugated liposomal doxorubicin with significantly improved therapeutic efficacy against anaplastic large cell lymphoma.

Abstract
The use of nano-carriers has been shown to improve the delivery and efficacy of chemotherapeutic agents in cancer patients. Recent studies suggest that decoration of the surface of nano-carriers with various targeting moieties may further improve the overall therapeutic efficacy. In this study, we compared the therapeutic efficacy of Doxil(®) (commercial doxorubicin-loaded liposomes) and that of Doxil(®) conjugated with anti-CD30 antibodies (CD30-targeted Doxil(®)) in treating anaplastic large cell lymphoma (ALCL), a type of T-cell lymphoma characterized by a high CD30 expression. Compared to Doxil(®), the CD30-targeted Doxil(®) showed a significantly higher binding affinity to ALCL cells (5.3% versus 27%, p = 0.005) and a lower inhibitory concentration at 50% (IC50) in-vitro (32.6 μg/mL versus 12.6 μg/mL, p = 0.006). In a SCID mouse xenograft model, CD30-targeted Doxil(®) inhibited tumor growth more significantly than the unconjugated formulation; specifically, tumors in mice treated with CD30-targeted Doxil(®) were significantly smaller than those in mice treated with Doxil(®) (average, 117 mm(3) versus 270 mm(3), p = 0.001) at 18 days after the tumors were inoculated. Our findings have provided the proof-of-principle of using CD30-targeted nano-carriers to treat cancers that are characterized by a high level of CD30 expression, such as ALCL.
AuthorsOmmoleila Molavi, Xiao-Bing Xiong, Donna Douglas, Norm Kneteman, Satoshi Nagata, Ira Pastan, Quincy Chu, Afsaneh Lavasanifar, Raymond Lai
JournalBiomaterials (Biomaterials) Vol. 34 Issue 34 Pg. 8718-8725 (Nov 2013) ISSN: 1878-5905 [Electronic] Netherlands
PMID23942212 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
Copyright© 2013 Elsevier Ltd. All rights reserved.
Chemical References
  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Ki-1 Antigen
  • liposomal doxorubicin
  • Polyethylene Glycols
  • Doxorubicin
Topics
  • Animals
  • Antibodies, Monoclonal (therapeutic use)
  • Antineoplastic Agents (therapeutic use)
  • Cell Line, Tumor
  • Disease Models, Animal
  • Doxorubicin (analogs & derivatives, therapeutic use)
  • Ki-1 Antigen (immunology)
  • Lymphoma, Large-Cell, Anaplastic (drug therapy)
  • Male
  • Mice
  • Mice, SCID
  • Nanoparticles (chemistry)
  • Polyethylene Glycols (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: